A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

A Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

The purpose of this study is to evaluate and compare the efficacy of B244 in treating patients with hypertension.

Study Overview

• Status: Completed
• Conditions: Prehypertension; Hypertension, Stage I
• Intervention / Treatment: Biological: B244; Biological: Vehicle

Detailed Description

This is a Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 4 weeks vs vehicle application on BP and inflammatory biomarkers.

• Study Type: Interventional
• Enrollment (Actual): 132
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35205
      • Central Research Associates
  • Arizona
    • Phoenix, Arizona, United States, 85018
      • Elite Clinical Studies
  • California
    • Tustin, California, United States, 92780
      • Orange County Research Center
  • Connecticut
    • Milford, Connecticut, United States, 06460
      • Clinical Research Consulting
  • Florida
    • Hialeah, Florida, United States, 33012
      • AGA Clinical Trials
  • Illinois
    • Chicago, Illinois, United States, 60611
      • ICCT Research International
  • Louisiana
    • Metairie, Louisiana, United States, 70006
      • MedPharmics
  • Maryland
    • Silver Spring, Maryland, United States, 20190
      • Alternative Primary Care (Einstein Clinical Research)
  • New York
    • Bronx, New York, United States, 10459
      • CHEAR Center
  • Texas
    • Humble, Texas, United States, 77338
      • Research Trials WorldWide

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female subjects ≥18 years of age
• In good general health as determined by a thorough medical history and physical examination, and vital signs

• Clinical diagnosis of elevated Blood Pressure defined as:

  • Having systolic prehypertension measurements having systolic BP (mmHg) of 120-139 and Diastolic BP (mmHg) of 90
  • OR
  • Having systolic Stage 1 hypertension measurements having systolic BP (mmHg) of 140-159 and Diastolic BP (mmHg) of 100
• Hypertension treatment naïve patients, defined as those patients who have never been treated with antihypertensive medications or have been off any hypertensive treatment for a period of 12 weeks or longer.
• Willing to refrain from using any antihypertensive treatments, other than the investigational product, including herbal supplements, systemic use of steroids, chronic use of NSAIDS, any antihypertensive agents, such as beta-blockers, diuretics, ACE inhibitors, CA channel blockers, Alpha blockers, Central Acting agents and vasodilators.
• Ability to comprehend and comply with procedures
• Agree to commit to participate in the current protocol
• Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read)

Exclusion Criteria:

• Pregnant and/or lactating women
• Patients on treatment for Benign Prostatic Hyperplasia (BPH)
• Clinically significant history of cardiovascular disease (i. e. PCI, CABG MI (if event occurred 12 months), atrial fibrillation, frequent PAC, cardiac rhythm disorder, syncope, valve repair/replacement, heart transplantation, PTA, peripheral bypass surgery, endarterectomy, unstable angina, TIA, stroke and NYHF category II, II and IV heart failure.
• Patients with renal failure, significant kidney or renal disease defined as having creatinine level of mg/dL
• Presence of any condition (medical, psychological, social, or geographical), actual or anticipated, that the Investigator feels would restrict or limit the patient's successful participation for the duration of the study
• History of migraines and/or anxiety, where patient is unable to refrain from the use of beta blockers
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.
• The participant has been previously randomized in this study
• Subjects with clinical diagnosis of Type I Diabetes
• Subjects with arm circumference of 42 cm
• Any condition that would prevent the subject from participating in the trial in the opinion of the evaluation physician
• The participant has received an investigational product within 30 days prior to randomization
• Prior use of any product containing B244 or Nitrosomonas eutropha
• Unable to lie flat or sit for 15 minutes
• Concurrent participation in other trials

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: B244 4 pumps applied to the face; 4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.	Biological: B244; odorless suspension
Active Comparator: B 244 8 Pumps applied to face and torso; 8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.	Biological: B244; odorless suspension
Sham Comparator: Vehicle 4 pumps applied to the face; 4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.	Biological: Vehicle; odorless suspension
Sham Comparator: Vehicle 8 pumps applied to face and torso; 8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.	Biological: Vehicle; odorless suspension

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0	Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.	Baseline-6 weeks
Difference in Mean in Clinic Systolic BP Between the Active and Vehicle Groups	Clinical systolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.	Baseline-Week 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in Mean in Clinic Diastolic BP Between the Active and Vehicle Group	Clinical diastolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.	Baseline-Week 4
Difference in Mean Ambulatory Systolic and Diastolic Daytime Blood Pressure	An ambulatory blood pressure measurement (ABPM) device was placed on a subject's arm during the clinic visit to record 24-hour blood pressure and heart rate measurements.	Baseline-Week 4

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in Inflammatory Biomarkers Between Active and Vehicle Groups	To evaluate if B244 administration on the skin twice daily will affect the levels of immune biomarkers.	Baseline-Week 4
Microbial Content	Evaluate if B244 administration on skin twice daily will affect the microbial content on collected skin swab samples.	Baseline, Day 28, Day 42
Microbial Composition	Evaluate if B244 administration on skin twice daily will affect the microbial composition on collected skin samples.	Baseline, Day 28, Day 42

Collaborators and Investigators

• Sponsor: AOBiome LLC
• Collaborators: Veristat, Inc.
• Investigators: Study Director: Larry Weiss, MD, Chief Medical Officer

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2016
• Primary Completion (Actual): April 25, 2017
• Study Completion (Actual): June 26, 2017

Study Registration Dates

• First Submitted: November 22, 2016
• First Submitted That Met QC Criteria: December 16, 2016
• First Posted (Estimate): December 21, 2016

Study Record Updates

• Last Update Posted (Actual): September 15, 2022
• Last Update Submitted That Met QC Criteria: August 23, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: elevated blood pressure
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Hypertension; Prehypertension
• Other Study ID Numbers: AVB244-003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO